Skip to content

For US Healthcare Professionals Only

Prescribing Information
Patient Site
Vevye Logo Vevye Logo Contact Us

The Difference Starts with The vehicle

VEVYE® utilizes a novel water-free semifluorinated alkane, perfluorobutylpentane.1

The Difference Starts with The vehicle

VEVYE® utilizes a novel water-free semifluorinated alkane, perfluorobutylpentane.1

A Bird’s Eye View

Perfluorobutylpentane

Semifluorinated alkanes (SFA), are colorless, amphiphilic, non-aqueous liquids that spread rapidly across the ocular surface.8

Due to the amphiphilic nature of SFAs, perfluorobutylpentane can effectively dissolve hydrophobic drugs like cyclosporine.8

The Vehicle Matters

Improves the Bioavailability of Cyclosporine 4

  • Amphiphilic vehicle that can dissolve hydrophobic drugs like cyclosporine8

  • Delivers ~22x more cyclosporine than Restasis® (cyclosporine ophthalmic emulsion) 0.05% into the cornea8*

See the Data

Low Surface Tension

  • Improves the lipid layer grading immediately after administration8

  • Allows for rapid and even spreading4,8

Residence Time

  • Detectable in tears for up to 8 hours4**

Improves the Bioavailability of Cyclosporine 4

  • Amphiphilic vehicle that can dissolve hydrophobic drugs like cyclosporine8

  • Delivers ~22x more cyclosporine than Restasis® (cyclosporine ophthalmic emulsion) 0.05% into the cornea8*

See the Data

Low Surface Tension

  • Improves the lipid layer grading immediately after administration8

  • Allows for rapid and even spreading4,8

Residence Time

  • Detectable in tears for up to 8 hours4**

*Ex-vivo porcine corneal penetration study using 50μl of tested formulations. Clinical relevance is not yet established.

**In a preclinical rabbit study. Clinical relevance is not yet established.

Cyclosporine Delivery

Ex Vivo Cyclosporine (CsA) Corneal Penetration 4*

CsA (ng/g cornea) Measurements

Perfluorobutylpentane delivered

~22x MORE CsA

into the cornea

than Restasis® (cyclosporine ophthalmic emulsion) 0.05%. 9*

Restasis® (cyclosporine ophthalmic emulsion) 0.05%

PFBP + cyclosporine 0.05%

Ikervis® (cyclosporine ophthalmic emulsion) 0.1%

VEVYE® (cyclosporine ophthalmic solution) 0.1%

Perfluorobutylpentane delivered

~22x MORE CsA

into the cornea

than Restasis® (cyclosporine ophthalmic emulsion) 0.05%. 9*

Ex Vivo Cyclosporine (CsA) Corneal Penetration 4*

CsA (ng/g cornea) Measurements

Swipe to view More

Restasis® (cyclosporine ophthalmic emulsion) 0.05%

PFBP + cyclosporine 0.05%

Ikervis® (cyclosporine ophthalmic emulsion) 0.1%

VEVYE® (cyclosporine ophthalmic solution) 0.1%

PFBP, perfluorobutylpentane. *Ex-vivo porcine corneal penetration study using 50μl of tested formulations. Clinical relevance is not yet established.

Saline

Perfluorobutylpentane

-5ms
0ms
2ms
5ms
10ms
20ms

The Molecule that moves

Perfluorobutylpentane’s low surface tension allows for rapid and even spreading across the corneal surface. 4,8

When tested against saline, the volume-adjusted spreadable area of perfluorobutylpentane was more than three times greater than saline (p<0.001) and had completely spread out within 20 milliseconds of contacting the cornea.8†

Study Design: The contact angle and spreading dynamics of perfluorobutylpentane and saline on the corneal surface were observed ex vivo using high-speed photography. Freshly excised porcine eyes were collected and those without visible damage were excised and laid flat on a glass slide after making six radial slits (∼2 mm long) at the edges of the cornea. A single drop of each test substance was dispensed from a height of 20 mm above the corneal surface using a 25- gauge needle. Drop impact was imaged using high speed cameras. The spread area was measured by manually outlining the drop perimeter from ‘top view’ images.

†Clinical relevance is not yet established.

time to try vevye

Connect with a representative to learn more.

Connect with a representative to learn more.

Contact Us

INDICATION AND USAGE

VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
  • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Adverse Reactions

In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about VEVYE, please see the Full Prescribing Information.